<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">To date, 73 (73%) deaths, occurring at a median of 2.5 years (range 0.06–6.9), and 15 (15%) leukemic transformations, occurring at a median of 3.6 years (range 0.12–7.2), have been recorded. Twenty-seven (27%) patients are currently alive and followed for a median of 6.6 years (range 5.5–7.2) from the time of study entry; among them, eight have received allogeneic stem cell transplant (ASCT) and were censored at the time of the procedure for survival analysis. Median survival from the time of study entry was 3.2 years with 5-year survival of 30%.</p>
